<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04925310</url>
  </required_header>
  <id_info>
    <org_study_id>MHH6309</org_study_id>
    <nct_id>NCT04925310</nct_id>
  </id_info>
  <brief_title>Infection With Respiratory Syncytial Virus in Infants</brief_title>
  <acronym>IRIS</acronym>
  <official_title>IRIS - Infection With Respiratory Syncytial Virus in Infants - a Prospective Observational Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hannover Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      IRIS (Infection with RespIratory Syncytial Virus) is an observational, multi-center study&#xD;
      enrolling infants with severe RSV infection and healthy controls. Inclusion criteria are age&#xD;
      below two years and hospitalization due to RSV infection at three German sites. Exclusion&#xD;
      criteria are premature birth, congenital or acquired bronchopulmonary or cardiac diseases,&#xD;
      and immunodeficiency. Blood and respiratory specimens are collected upon admission, and RSV&#xD;
      and other pathogens are analyzed by multiplex polymerase chain reaction (PCR). Further&#xD;
      biomaterials including plasma, nasal lining fluid, blood cells, DNA, and RNA specimens are&#xD;
      sampled in a dedicated biobank. Detailed information on demographic characteristics and&#xD;
      medical history is recorded, as well as comprehensive clinical data including vital signs,&#xD;
      medication, and interventions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The IRIS study is designed as a multicentric, prospective, observational study initiated at&#xD;
      Hannover Medical School, Germany. Upon enrollment, detailed data on demographic background,&#xD;
      case histo-ry, clinical presentation, physical examination, diagnostic findings, treatment,&#xD;
      and other patient related items is collected. Data on disease course, treatment, and&#xD;
      complications is gathered. Blood and respiratory specimens are collected upon admission, and&#xD;
      RSV and other pathogens are analyzed by multiplex polymerase chain reaction (PCR). Further&#xD;
      biomaterials including plasma, nasal lining fluid, blood cells, DNA, and RNA specimens are&#xD;
      sampled in a dedicated biobank (Hannover Unified Biobank). The study enrolls hospitalized&#xD;
      children with confirmed RSV infection between the first month of life and second year of&#xD;
      life. The diagnosis of RSV is evaluated by point-of-care testing (POCT, Sofia, Quidel,&#xD;
      Kornwestheim, Germany), and positive findings are confirmed by polymerase chain reac-tion&#xD;
      (PCR). Exclusion criteria are premature birth, congenital or acquired bronchopulmonary or&#xD;
      car-diac diseases, and immunodeficiency. Healthy control probands are enrolled via&#xD;
      recruitment of patients undergoing routine surgical procedures. Written informed consent is&#xD;
      obtained from all parents and caregivers. Three local study centers in northern Germany&#xD;
      (Hannover, Oldenburg, and Hildesheim) are contributing. All study sites are secondary or&#xD;
      tertiary care hospitals and undergo extensive training in recruitment, biosample acquisition&#xD;
      and processing, data collection and data entry, logistics, and security.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2013</start_date>
  <completion_date type="Anticipated">October 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Month</target_duration>
  <primary_outcome>
    <measure>Incidence of severe RSV infection</measure>
    <time_frame>5 years</time_frame>
    <description>Number of patients with severe RSV infection in three tertiary care centers in northern Germany.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Outcome meassures of severe RSV infection in children (composite endpoint)</measure>
    <time_frame>5 years</time_frame>
    <description>length of hospitalisation (days)&#xD;
length of additional oxygen supply (hours)&#xD;
number of patients with need for intensive care treatment&#xD;
number of patients with need for invasive ventilation</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Respiratory Syncytial Virus Infections</condition>
  <condition>Respiratory Syncytial Virus (RSV)</condition>
  <condition>Respiratory Syncytial Virus-bronchiolitis</condition>
  <arm_group>
    <arm_group_label>RSV Bronchiolitis Group</arm_group_label>
    <description>hospitalized children with confirmed RSV infection between the first month of life and second year of life</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Nasopharyngeal aspirate or swab for PCR pathogen screening Nasal fluid EDTA whole blood Serum&#xD;
      Plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study enrolls hospitalized children with confirmed RSV infection between the first&#xD;
        month of life and second year of life. The diagnosis of RSV is evaluated by point-of-care&#xD;
        testing, and positive findings are confirmed by polymerase chain reac-tion (PCR). Exclusion&#xD;
        criteria are premature birth, congenital or acquired bronchopulmonary or car-diac diseases,&#xD;
        and immunodeficiency.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  RSV Infection, confirmed by polymerase chain reaction (PCR)&#xD;
&#xD;
          -  Need for hospitalisation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  premature birth&#xD;
&#xD;
          -  bronchopulmonary diseases&#xD;
&#xD;
          -  cardiac diseases&#xD;
&#xD;
          -  immunodeficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>2 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hansen Gesine, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martin Wetzke, MD</last_name>
    <phone>0049 511 532 7436</phone>
    <email>wetzke.martin@mh-hannover.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Pietschmann, Prof</last_name>
    <phone>0049 511 532 7130</phone>
    <email>pietschmann.thomas@mh-hannover.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hanover</city>
        <state>Lower Saxony</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Wetzke, MD</last_name>
      <phone>0049 511 532 3220</phone>
      <email>wetzke.martin@mh-hannover.de</email>
    </contact>
    <contact_backup>
      <last_name>Gesine Hansen, Prof</last_name>
      <phone>0049 511 532 3220</phone>
      <email>hansen.gesine@mh-hannover.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Kinder- und Jugendmedizin Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <state>Lower Saxony</state>
        <zip>26111</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jürgen Seidenberg, Prof</last_name>
      <phone>0049 441 798 3540</phone>
      <email>seidenberg.juergen@klinikum-oldenburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Mathias Lange, MD</last_name>
      <phone>0049 441 798 3540</phone>
      <email>Lange.Matthias@klinikum-oldenburg.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 20, 2021</study_first_submitted>
  <study_first_submitted_qc>June 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2021</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Respiratory Syncytial Virus (RSV)</keyword>
  <keyword>Infants</keyword>
  <keyword>bronchiolitis</keyword>
  <keyword>infection</keyword>
  <keyword>cohort study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Bronchiolitis</mesh_term>
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

